FindTrial
Sign In

Transcriptomics reveals marker genes and immune infiltration in extramammary Paget's disease

Transcriptomics reveals marker genes and immune infiltration in extramammary Paget's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096062
Enrollment
Unknown
Registered
2025-01-16
Start date
2023-11-13
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extramammary Paget's disease

Interventions

Control:None
EMPD:None

Sponsors

Ningbo First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1.patients with EMPD confirmed by hematoxylin-eosin (HE) staining and immunostaining at the Pathology Center of the First Affiliated Hospital of Ningbo University.

Exclusion criteria

Exclusion criteria: 1.Patients with an unclear pathological diagnosis of extramammary Paget's disease;

Design outcomes

Primary

MeasureTime frame
heal;—

Countries

China

Contacts

Public ContactZhu Xiaoxia

Ningbo First Hospital

nb_zhuxiaoxia@126.com+86 139 5788 3028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026